MCID: SKN015
MIFTS: 71

Skin Carcinoma

Categories: Cancer diseases, Rare diseases, Skin diseases

Aliases & Classifications for Skin Carcinoma

MalaCards integrated aliases for Skin Carcinoma:

Name: Skin Carcinoma 12 54 15 17
Skin Cancer 12 20 54 6 42 3 15
Melanoma and Non-Melanoma Skin Cancer 12
Malignant Neoplasm of Skin 12
Carcinoma of Skin 12
Ca - Skin Cancer 12
Cancer of Skin 12
Skin Cancers 15
Cancer, Skin 39

Classifications:



External Ids:

Disease Ontology 12 DOID:3451 DOID:4159
MeSH 44 D012878
NCIt 50 C2920 C4914
SNOMED-CT 67 94047004
UMLS 70 C0007114 C0699893

Summaries for Skin Carcinoma

MedlinePlus : 42 Skin cancer is the most common form of cancer in the United States. The two most common types are basal cell cancer and squamous cell cancer. They usually form on the head, face, neck, hands, and arms. Another type of skin cancer, melanoma, is more dangerous but less common. Anyone can get skin cancer, but it is more common in people who Spend a lot of time in the sun or have been sunburned Have light-colored skin, hair and eyes Have a family member with skin cancer Are over age 50 You should have your doctor check any suspicious skin markings and any changes in the way your skin looks. Treatment is more likely to work well when cancer is found early. If not treated, some types of skin cancer cells can spread to other tissues and organs. Treatments include surgery, radiation therapy, chemotherapy, photodynamic therapy (PDT), and biologic therapy. PDT uses a drug and a type of laser light to kill cancer cells. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

MalaCards based summary : Skin Carcinoma, also known as skin cancer, is related to squamous cell carcinoma and skin squamous cell carcinoma. An important gene associated with Skin Carcinoma is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Vemurafenib and Ipilimumab have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and prostate, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An integumentary system cancer located in the skin that is the uncontrolled growth of abnormal skin cells.

CDC : 3 Skin cancer is the most common form of cancer in the United States. The two most common types of skin cancer-basal cell and squamous cell carcinomas-are highly curable, but can be disfiguring and costly to treat. Melanoma, the third most common skin cancer, is more dangerous and causes the most deaths. The majority of cases of these three types of skin cancer are caused by overexposure to ultraviolet (UV) light.

Related Diseases for Skin Carcinoma

Diseases in the Skin Carcinoma family:

Skin Carcinoma in Situ

Diseases related to Skin Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 858)
# Related Disease Score Top Affiliating Genes
1 squamous cell carcinoma 33.2 TP53 PTEN PIK3CA MAP2K1 HRAS CTNNB1
2 skin squamous cell carcinoma 33.2 TP53 RAF1 HRAS CDKN2A BRAF
3 prostate cancer 33.1 TP53 RAF1 PTEN PIK3CA PDGFRA MAP2K1
4 squamous cell carcinoma, head and neck 32.9 TP53 PTEN PIK3CA MAP2K1 HRAS CTNNB1
5 large congenital melanocytic nevus 32.8 NRAS MITF MC1R HRAS GNAQ GNA11
6 basal cell nevus syndrome 32.8 TP53 PTEN MC1R CTNNB1 AKT1
7 basal cell carcinoma 32.7 TP53 PTEN MC1R KIT CTNNB1 CDKN2A
8 acral lentiginous melanoma 32.7 PTEN NRAS MC1R KIT HRAS CDKN2A
9 cowden syndrome 32.5 TP53 PTEN PIK3CA HRAS CTNNB1 AKT1
10 piebald trait 32.4 PDGFRA MITF MC1R KIT
11 lentigo maligna melanoma 32.3 MITF MC1R
12 melanoma, cutaneous malignant 1 32.0 TP53 RAF1 PTEN NRAS MITF MC1R
13 melanoma 31.8 TP53 SNAPC5 RAF1 PTEN PIK3CA PDGFRA
14 skin melanoma 31.8 TP53 SNAPC5 RAF1 PTEN PIK3CA PDGFRA
15 lentigines 31.8 RAF1 MC1R BRAF
16 breast cancer 31.7 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
17 dermatofibrosarcoma protuberans 31.7 TP53 PDGFRA KIT CDKN2A CDK4
18 glioblastoma 31.5 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
19 lymphoma, non-hodgkin, familial 31.5 TP53 PIK3CA NRAS MAP2K1 BRAF AKT1
20 adenoid cystic carcinoma 31.5 TP53 PTEN PIK3CA KIT HRAS CTNNB1
21 melanoma, uveal 31.4 TP53 RAF1 PTEN PIK3CA NRAS MITF
22 keratosis 31.4 TP53 PIK3CA HRAS CDKN2A
23 merkel cell carcinoma 31.4 TP53 PDGFRA KIT CTNNB1 CDKN2A
24 adenocarcinoma 31.4 TP53 RAF1 PTEN PIK3CA MAP2K1 KIT
25 sarcoma 31.4 TP53 RAF1 PIK3CA PDGFRA NRAS KIT
26 nodular malignant melanoma 31.4 TP53 NRAS MITF MC1R KIT HRAS
27 myeloma, multiple 31.3 TP53 PTEN PIK3CA NRAS KIT HRAS
28 bladder cancer 31.3 TP53 PTEN PIK3CA NRAS MAP2K1 HRAS
29 actinic keratosis 31.3 TP53 MITF MC1R HRAS CTNNB1 CDKN2A
30 melanoma in congenital melanocytic nevus 31.3 RAF1 NRAS MITF MC1R KIT HRAS
31 small cell carcinoma 31.3 TP53 PTEN PDGFRA KIT CDKN2A
32 lung cancer 31.3 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
33 ovarian cancer 31.2 TP53 RAF1 PTEN PIK3CA PDGFRA MAP2K1
34 alzheimer disease 31.2 TP53 RAF1 PTEN MAP2K1 HRAS GNAQ
35 skin papilloma 31.2 TP53 PTEN HRAS AKT1
36 medulloblastoma 31.2 TP53 PTEN PIK3CA PDGFRA NRAS MAP2K1
37 leukemia, acute myeloid 31.2 TP53 PTEN PIK3CA PDGFRA NRAS MAP2K1
38 leukemia, chronic myeloid 31.2 TP53 RAF1 PDGFRA NRAS KIT HRAS
39 lung cancer susceptibility 3 31.1 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
40 neuroblastoma 31.1 TP53 PTEN PIK3CA NRAS MAP2K1 KIT
41 verrucous carcinoma 31.1 TP53 PTEN CDKN2A
42 renal cell carcinoma, nonpapillary 31.1 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
43 myeloid leukemia 31.1 TP53 RAF1 NRAS MAP2K1 KIT HRAS
44 endometrial cancer 31.1 TP53 PTEN PIK3CA PDGFRA NRAS HRAS
45 cervical cancer 31.1 TP53 PTEN PIK3CA HRAS CTNNB1 CDKN2A
46 kidney cancer 31.1 TP53 PTEN PIK3CA CDKN2A AKT1
47 myelodysplastic syndrome 31.1 TP53 PTEN NRAS KIT HRAS CDKN2A
48 li-fraumeni syndrome 31.1 TP53 PTEN HRAS CTNNB1 CDKN2A CDK4
49 exanthem 31.0 KIT HRAS AKT1
50 nasopharyngeal carcinoma 31.0 TP53 PTEN PIK3CA NRAS HRAS CTNNB1

Graphical network of the top 20 diseases related to Skin Carcinoma:



Diseases related to Skin Carcinoma

Symptoms & Phenotypes for Skin Carcinoma

GenomeRNAi Phenotypes related to Skin Carcinoma according to GeneCards Suite gene sharing:

26 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.77 BRAF PIK3CA HRAS
2 Decreased viability GR00055-A-2 10.77 BRAF PIK3CA HRAS
3 Decreased viability GR00107-A-1 10.77 MAP2K1
4 Decreased viability GR00173-A 10.77 PDGFRA
5 Decreased viability GR00221-A-1 10.77 AKT1 CDKN2A PDGFRA PIK3CA HRAS NRAS
6 Decreased viability GR00221-A-2 10.77 AKT1 PIK3CA HRAS RAF1
7 Decreased viability GR00221-A-3 10.77 AKT1 CDKN2A PDGFRA HRAS MAP2K1 NRAS
8 Decreased viability GR00221-A-4 10.77 AKT1 BRAF CDKN2A PDGFRA PIK3CA
9 Decreased viability GR00249-S 10.77 AKT1 BRAF PDGFRA
10 Decreased viability GR00301-A 10.77 BRAF KIT RAF1
11 Decreased viability GR00381-A-1 10.77 BRAF
12 Decreased viability GR00402-S-2 10.77 PDGFRA PIK3CA RAF1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.45 KIT
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-115 10.45 CDK4
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-116 10.45 CDK4 PIK3CA
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.45 PTEN
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-157 10.45 PIK3CA
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-16 10.45 AKT1 PIK3CA
19 Decreased shRNA abundance (Z-score < -2) GR00366-A-165 10.45 KIT
20 Decreased shRNA abundance (Z-score < -2) GR00366-A-166 10.45 PIK3CA
21 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 10.45 AKT1 PIK3CA
22 Decreased shRNA abundance (Z-score < -2) GR00366-A-18 10.45 KIT
23 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.45 PIK3CA
24 Decreased shRNA abundance (Z-score < -2) GR00366-A-21 10.45 CDK4
25 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 10.45 PIK3CA
26 Decreased shRNA abundance (Z-score < -2) GR00366-A-42 10.45 AKT1 CDK4 KIT PIK3CA
27 Decreased shRNA abundance (Z-score < -2) GR00366-A-46 10.45 CDK4
28 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 10.45 PIK3CA
29 Decreased shRNA abundance (Z-score < -2) GR00366-A-50 10.45 AKT1
30 Decreased shRNA abundance (Z-score < -2) GR00366-A-53 10.45 CDK4 PIK3CA
31 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 10.45 CDK4
32 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.45 AKT1
33 Decreased substrate adherent cell growth GR00193-A-1 9.86 KIT
34 Decreased substrate adherent cell growth GR00193-A-2 9.86 CDK4 KIT
35 Decreased substrate adherent cell growth GR00193-A-3 9.86 BRAF CDK4
36 Decreased substrate adherent cell growth GR00193-A-4 9.86 BRAF CDK4 KIT
37 Decreased cell migration GR00055-A-1 9.77 AKT1 CDK4
38 Decreased cell migration GR00055-A-3 9.77 BRAF HRAS PIK3CA
39 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.65 CTNNB1
40 Increased transferrin (TF) endocytosis (mild increase), increased transferrin (TF) endosome elongation GR00363-A 8.32 HRAS

MGI Mouse Phenotypes related to Skin Carcinoma:

46 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.59 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
2 growth/size/body region MP:0005378 10.57 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
3 cardiovascular system MP:0005385 10.56 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
4 endocrine/exocrine gland MP:0005379 10.55 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
5 homeostasis/metabolism MP:0005376 10.54 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
6 cellular MP:0005384 10.53 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
7 integument MP:0010771 10.53 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
8 craniofacial MP:0005382 10.49 BRAF CDK4 CTNNB1 FBN1 GNA11 GNAQ
9 immune system MP:0005387 10.49 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
10 embryo MP:0005380 10.48 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
11 hematopoietic system MP:0005397 10.48 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
12 mortality/aging MP:0010768 10.46 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
13 nervous system MP:0003631 10.39 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
14 muscle MP:0005369 10.37 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
15 digestive/alimentary MP:0005381 10.35 BRAF CDK4 CDKN2A CTNNB1 HRAS KIT
16 neoplasm MP:0002006 10.35 AKT1 BRAF CDK4 CDKN2A CTNNB1 HRAS
17 limbs/digits/tail MP:0005371 10.31 BRAF CTNNB1 FBN1 GNA11 GNAQ KIT
18 liver/biliary system MP:0005370 10.3 AKT1 BRAF CDK4 CDKN2A CTNNB1 GNA11
19 hearing/vestibular/ear MP:0005377 10.28 BRAF CTNNB1 GNA11 GNAQ KIT MAP2K1
20 normal MP:0002873 10.28 AKT1 BRAF CDK4 CTNNB1 GNA11 GNAQ
21 no phenotypic analysis MP:0003012 10.21 CDKN2A CTNNB1 FBN1 HRAS KIT MC1R
22 pigmentation MP:0001186 10.21 BRAF CDK4 CDKN2A CTNNB1 FBN1 GNA11
23 renal/urinary system MP:0005367 10.1 BRAF CDK4 CTNNB1 FBN1 GNA11 GNAQ
24 reproductive system MP:0005389 10.07 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
25 respiratory system MP:0005388 9.97 AKT1 BRAF CDKN2A CTNNB1 FBN1 GNA11
26 skeleton MP:0005390 9.91 AKT1 BRAF CDK4 CDKN2A CTNNB1 FBN1
27 vision/eye MP:0005391 9.4 BRAF CDK4 CDKN2A CTNNB1 KIT MAP2K1

Drugs & Therapeutics for Skin Carcinoma

Drugs for Skin Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 209)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vemurafenib Approved Phase 4 918504-65-1 23252090 42611257
2
Ipilimumab Approved Phase 4 477202-00-9
3
Aldesleukin Approved Phase 4 110942-02-4, 85898-30-2
4
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
5
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
6
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030
7
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Azathioprine Approved Phase 4 446-86-6 2265
10
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
11 Immunosuppressive Agents Phase 4
12 Immunologic Factors Phase 4
13 Anti-Infective Agents Phase 4
14 Antimetabolites Phase 4
15 Antiviral Agents Phase 4
16 Dermatologic Agents Phase 4
17 Antirheumatic Agents Phase 4
18 Neurotransmitter Agents Phase 4
19 Antineoplastic Agents, Immunological Phase 4
20 Anti-Retroviral Agents Phase 4
21 Anti-HIV Agents Phase 4
22 Interleukin-2 Phase 4
23 Antifungal Agents Phase 4
24 Antibiotics, Antitubercular Phase 4
25 Anti-Bacterial Agents Phase 4
26 Calcineurin Inhibitors Phase 4
27 Cyclosporins Phase 4
28 abobotulinumtoxinA Phase 4
29 Hemagglutinins Phase 4
30 Cholinergic Agents Phase 4
31 Agglutinins Phase 4
32 Botulinum Toxins, Type A Phase 4
33 Botulinum Toxins Phase 4
34
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
35
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
36
Acetaminophen Approved Phase 3 103-90-2 1983
37
Imiquimod Approved, Investigational Phase 3 99011-02-6 57469
38
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
39
leucovorin Approved Phase 3 58-05-9 6006
40
Trametinib Approved Phase 3 871700-17-3 11707110
41
Dabrafenib Approved, Investigational Phase 3 1195765-45-7 44462760 44516822
42 interferons Phase 3
43 Sunscreening Agents Phase 3
44 Methyl 5-aminolevulinate Phase 3
45 Protective Agents Phase 2, Phase 3
46 Radiation-Protective Agents Phase 2, Phase 3
47 Adjuvants, Immunologic Phase 3
48 Antipyretics Phase 3
49 Immunoglobulins Phase 3
50 Antibodies Phase 3

Interventional clinical trials:

(show top 50) (show all 287)
# Name Status NCT ID Phase Drugs
1 Photosensitivity of the Skin Under Azathioprin in Renal Transplant Recipients Completed NCT00492895 Phase 4 Discontinuation of Azathioprin
2 A Randomized, Open-Label Study to Compare the Rate of New Non-Melanoma Skin Cancer in Maintenance Renal Allograft Recipients Converted to a Sirolimus-based Regimen Versus Continuation of a Calcineurin Inhibitor-based Regimen Completed NCT00129961 Phase 4 sirolimus;cyclosporine or tacrolimus
3 A Multi-Center Study of High Dose Aldesleukin (Interleukin-2) + Vemurafenib Therapy in Patients With BRAFV600 Mutation Positive Metastatic Melanoma Terminated NCT01683188 Phase 4 vemurafenib + HD IL-2
4 Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma Terminated NCT01856023 Phase 4 High Dose Interleukin-2;Ipilimumab
5 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT01797315 Phase 4 Sirolimus
6 A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of AbobotulinumtoxinA (BTX-A) in Improving Forehead Wounds After Mohs Micrographic Surgery and Reconstruction for Skin Cancer Terminated NCT01459666 Phase 4 Dysport (abobotulinumtoxinA);Bacteriostatic 0.9% Sodium Chloride (vehicle)
7 Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive Protocol Terminated NCT00866684 Phase 4 Sirolimus;Azathioprine;Mycophenolate;Ciclosporin;Tacrolimus
8 CERTICOEUR a Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. An Open Labelled Randomized Everolimus vs Calcineurin Inhibitors Multicenter Trial Unknown status NCT00799188 Phase 3 Everolimus
9 A Randomized, Double-Blind, Multicenter Study Comparing MDX-010 Monotherapy, MDX-010 in Combination With a Melanoma Peptide Vaccine, and Melanoma Vaccine Monotherapy in HLA-A2*0201-Positive Patients With Previously Treated Unresectable Stage III or IV Melanoma Completed NCT00094653 Phase 3 MDX-010 (anti-CTLA4) monoclonal antibody
10 Sun Safe Partners Online: Pilot Randomized Controlled Clinical Trial Completed NCT04549675 Phase 3
11 Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients - Multicentric Randomized, Open-label Study of Rapamycin vs Calcineurin Inhibitors Completed NCT00133887 Phase 3 rapamycin;ciclosporine;tacrolimus
12 Chemoprevention of Skin Cancers With DFMO: A Controlled, Randomized Clinical Trial Completed NCT00005884 Phase 3 eflornithine
13 Impact of Preoperative Acetaminophen and Carbohydrate Loading to on Pain and Functional Status in Patients Undergoing Mohs Micrographic Surgery for Non-melanoma Skin Cancers Completed NCT03131713 Phase 3 Acetaminophen
14 A Randomized Controlled Trial of Excisional Surgery Versus Imiquimod 5% Cream for Nodular and Superficial Basal Cell Carcinoma Completed NCT00066872 Phase 3 imiquimod
15 A Randomized Control Trial of Sun Protection Interventions for Operating Engineers Completed NCT01804595 Phase 2, Phase 3
16 Prospective Study To Determine Whether Tissue Scoring Results In Noticeable Marks Following Mohs Micrographic Surgery Completed NCT00367042 Phase 2, Phase 3
17 Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy in High-risk Cutaneous Squamous Cell Carcinoma of the Head and Neck Completed NCT00193895 Phase 3 Carboplatin
18 A Multicentre, Randomised Study of Photodynamic Therapy(PDT) With Metvix® 160 mg/g Cream in Immuno-compromised Patients With Non-melanoma Skin Cancer Completed NCT00472459 Phase 3
19 A Personalized Approach to Skin Cancer Prevention Among Adolescents Recruiting NCT04341064 Phase 3
20 A Randomized Phase 3 Comparison of IMO-2125 With Ipilimumab Versus Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma (ILLUMINATE-301) Active, not recruiting NCT03445533 Phase 3 Ipilimumab;IMO-2125;Ipilimumab
21 A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma Active, not recruiting NCT02967692 Phase 3 Dabrafenib;Trametinib
22 Effect of Cryotherpy on Hypertrophic Scar Active, not recruiting NCT04532840 Phase 2, Phase 3
23 Investigation of the Effectiveness of Non-Coherent Blue Light in Intralesional Photodynamic of Basal Cell Carcinoma Unknown status NCT00747903 Phase 2 aminolevulinic acid hydrochloride
24 A Phase I/II Pilot Study of Bioimmunotherapy With IRESSA (Gefitinib) and Pegylated Interferon Alpha-2a for Patients With Unresectable/Metastatic Squamous Cell Carcinoma of the Skin Unknown status NCT00423397 Phase 1, Phase 2 gefitinib
25 Skin Cancer Prophylaxis by Low-Fat Dietary Intervention Unknown status NCT00003097 Phase 2
26 Transient Infrared Imaging for Early Detection of Skin Cancer Unknown status NCT02154451 Phase 1, Phase 2
27 A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients. Unknown status NCT00829192 Phase 2 Afamelanotide (CUV1647);Placebo
28 Phase I/II Trial of the Combination of Decitabine and Temozolomide in the Treatment of Patients With Metastatic Melanoma Completed NCT00715793 Phase 1, Phase 2 Decitabine;Temozolomide
29 Phase IIB Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine and Topical Diclofenac in the Treatment of Sun-Damaged Skin on the Forearm Completed NCT00601640 Phase 2 Diclofenac Na gel;Eflornithine HCL ointment
30 Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma Completed NCT00885534 Phase 2 Cisplatin, Vinblastine, Temozolomide
31 Photochemical Tissue Bonding (PTB) for Excisional Wound Healing Completed NCT00586040 Phase 2
32 Fluorescein for Lymphatic Mapping and Sentinel Lymph Node Biopsy in Patients With Stage I and II Malignant Melanoma Completed NCT00847522 Phase 1, Phase 2 Fluorescein
33 Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma Completed NCT01327053 Phase 2 LDE225
34 Chemoprevention of Squamous Cell Cancer of the Skin in High Risk Patients Completed NCT02347813 Phase 2 Pioglitazone
35 Phase II Evaluation of Peptide Immunization and LMB-2 in Metastatic Melanoma Completed NCT00295958 Phase 2
36 Investigation of a Behavioral Substitute for Sunbathing Completed NCT00403377 Phase 1, Phase 2
37 A Phase 2 Study of Dasatinib in Patients With Transplant and Non-Transplant Related Unresectable or Metastatic Cutaneous Squamous Cell Carcinoma and RAI Stage 0-1 Chronic Lymphocytic Leukemia Completed NCT00563290 Phase 2 dasatinib
38 Prospective Randomized Comparative Study of Cell Transfer Therapy Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-dose Aldesleukin in Metastatic Melanoma Completed NCT01118091 Phase 2
39 Phase II Study in Patients With Metastatic Melanoma Using a Non-Myeloablative Lymphocyte Depleting Regimen of Chemotherapy Followed by Infusion of gp100 Reactive Peripheral Blood Lymphocytes (PBL) and High or Low Dose Aldesleukin Completed NCT00665470 Phase 2 Aldesleukin
40 Skin Cancer Prevention in a Pediatric Population Completed NCT01464957 Phase 2
41 A Phase II Randomized, Open-label Study Investigating the Healing Effects of HP802-247 Versus Antibiotic Ointment in Mohs Micrographic Surgery Patients Completed NCT01359735 Phase 2
42 A Phase II Trial of 4-5 Hour and 18-24 Hour Applications of 20% Topical ALA for Photodynamic Therapy of Cutaneous Carcinomas and Actinic Keratoses Completed NCT00002975 Phase 2 aminolevulinic acid
43 Cutaneous Absorption and Intralesional Penetration of Topical Amino-Levulinic Acid in Basal Cell Carcinoma and Squamous Cell Carcinoma as Measured by In Situ Fluorescence and Intensified Video Fluorescence Microscopy Completed NCT00002963 Phase 2 aminolevulinic acid hydrochloride
44 A Phase II Study of ZD1839 and Radiation in Patients With Squamous Cell Carcinoma of the Skin Completed NCT00126555 Phase 2 Gefitinib
45 A Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor, in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Completed NCT00054691 Phase 2 Iressa
46 Phase IIB Randomized, Double-Blinded, Placebo Controlled Study to Evaluate the Safety and Efficacy of Topical Difluoromethylornithine (DFMO) With and Without a Topical Corticosteroid Cream (Triamcinolone 0.1%) in the Therapy of Actinic Keratoses (AK) on the Forearms Completed NCT00021294 Phase 2 eflornithine;triamcinolone
47 A Phase II Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Celecoxib in Subjects With Basal Cell Nevus Syndrome Completed NCT00023621 Phase 2 celecoxib
48 Phase 2b Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients (OTR) Completed NCT00204789 Phase 2 Difluoromethylornithine
49 A Phase IIb Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Topical Bacteriophage T4 Endonuclease V in Renal Allograft Recipients With a History of Non-melanoma Skin Cancer Completed NCT00089180 Phase 2 liposomal T4N5 lotion
50 A Phase II Randomized, Double-Blind, Vehicle-Controlled, Crossover Clinical Trial of Tazarotene 0.1% and Vehicle Cream Each Applied Once-Daily for 12 or 24 Months in Subjects With Basal Cell Nevus Syndrome Completed NCT00783965 Phase 2 tazarotene

Search NIH Clinical Center for Skin Carcinoma

Genetic Tests for Skin Carcinoma

Anatomical Context for Skin Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Skin Carcinoma:

19
Skin

MalaCards organs/tissues related to Skin Carcinoma:

40
Skin, Eye, Prostate, Breast, Thyroid, Lung, Lymph Node

Publications for Skin Carcinoma

Articles related to Skin Carcinoma:

(show top 50) (show all 19929)
# Title Authors PMID Year
1
Receptor function, dominant negative activity and phenotype correlations for MC1R variant alleles. 6 61 54
17616515 2007
2
MC1R gene variants and non-melanoma skin cancer: a pooled-analysis from the M-SKIP project. 6 61
26103569 2015
3
Malignant Melanoma with Concurrent BRAF E586K and NRAS Q81K Mutations. 6 61
24926260 2014
4
Novel oxidative stress-related prognostic biomarkers for melanoma associated with tumor metastasis. 42 61
33663112 2021
5
Codon-specific translation reprogramming promotes resistance to targeted therapy. 6
29925953 2018
6
A somatic mutation in erythro-myeloid progenitors causes neurodegenerative disease. 6
28854169 2017
7
The MITF, p.E318K Variant, as a Risk Factor for Pheochromocytoma and Paraganglioma. 6
27680874 2016
8
Prevalence of MITF p.E318K in Patients With Melanoma Independent of the Presence of CDKN2A Causative Mutations. 6
26650189 2016
9
Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. 6
26775776 2016
10
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade. 6
26678033 2016
11
Updated field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma: the MelGene database. 6
25407435 2015
12
BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. 6
24710085 2015
13
Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors. 6
25656898 2015
14
Molecular characterization of melanoma cases in Denmark suspected of genetic predisposition. 6
25803691 2015
15
First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. 6
25370471 2015
16
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
17
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies. 6
25079330 2014
18
A meta-analysis of somatic mutations from next generation sequencing of 241 melanomas: a road map for the study of genes with potential clinical relevance. 6
24755198 2014
19
Transcriptome sequencing of melanocytic nevi and melanomas from Grm1 transgenic mice to determine melanoma driver mutations. 6
24661573 2014
20
Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. 6
24918823 2014
21
The GIST of targeted therapy for malignant melanoma. 6
24531699 2014
22
MITF E318K's effect on melanoma risk independent of, but modified by, other risk factors. 6
24406078 2014
23
Copper is required for oncogenic BRAF signalling and tumorigenesis. 6
24717435 2014
24
Prognostic value of BRAF mutations in localized cutaneous melanoma. 6
24388723 2014
25
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma. 6
24583796 2014
26
Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. 6
24576830 2014
27
Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. 6
24448821 2014
28
Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study. 6
24767713 2014
29
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 6
24670642 2014
30
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. 6
24508103 2014
31
Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas. 6
24512911 2014
32
The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. 6
24265153 2014
33
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition. 6
24265154 2014
34
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition. 6
24265152 2014
35
Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. 6
24265155 2014
36
Phenotypic characterization of nevus and tumor patterns in MITF E318K mutation carrier melanoma patients. 6
23774529 2014
37
The impact of MITF on melanoma development: news from bench and bedside. 6
24352080 2014
38
BRAF-V600 mutations have no prognostic impact in stage IV melanoma patients treated with monochemotherapy. 6
24586605 2014
39
Large-scale analysis of PDGFRA mutations in melanomas and evaluation of their sensitivity to tyrosine kinase inhibitors imatinib and crenolanib. 6
24132921 2013
40
MITF mutations associated with pigment deficiency syndromes and melanoma have different effects on protein function. 6
23787126 2013
41
Distribution of MC1R variants among melanoma subtypes: p.R163Q is associated with lentigo maligna melanoma in a Mediterranean population. 6
23647022 2013
42
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. 6
23918947 2013
43
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. 6
23775962 2013
44
C-RAF mutations confer resistance to RAF inhibitors. 6
23737487 2013
45
Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. 6
23833300 2013
46
Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. 6
23614898 2013
47
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. 6
23715574 2013
48
Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells. 6
23582185 2013
49
Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma. 6
23538902 2013
50
A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence. 6
23685455 2013

Variations for Skin Carcinoma

ClinVar genetic disease variations for Skin Carcinoma:

6 (show top 50) (show all 175)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MAP2K1 NM_002755.3(MAP2K1):c.607G>A (p.Glu203Lys) SNV Pathogenic 375982 rs1057519733 GRCh37: 15:66774131-66774131
GRCh38: 15:66481793-66481793
2 BRAF NM_004333.6(BRAF):c.1782T>A (p.Asp594Glu) SNV Pathogenic 375945 rs121913337 GRCh37: 7:140453153-140453153
GRCh38: 7:140753353-140753353
3 MAP2K1 , SNAPC5 NM_002755.4(MAP2K1):c.1144A>C (p.Asn382His) SNV Pathogenic 375984 rs1057519735 GRCh37: 15:66782915-66782915
GRCh38: 15:66490577-66490577
4 BRAF NM_004333.6(BRAF):c.1789_1790delinsTC (p.Leu597Ser) Indel Pathogenic 375942 rs121913368 GRCh37: 7:140453145-140453146
GRCh38: 7:140753345-140753346
5 NRAS NM_002524.5(NRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic 40471 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124
6 BRAF NM_004333.6(BRAF):c.1799_1800delinsAT (p.Val600Asp) Indel Pathogenic 375939 rs121913377 GRCh37: 7:140453135-140453136
GRCh38: 7:140753335-140753336
7 BRAF NM_004333.6(BRAF):c.1798_1799delinsAG (p.Val600Arg) Indel Pathogenic 375940 rs121913227 GRCh37: 7:140453136-140453137
GRCh38: 7:140753336-140753337
8 NRAS NM_002524.5(NRAS):c.182_183delinsTG (p.Gln61Leu) Indel Pathogenic 375872 rs1057519695 GRCh37: 1:115256528-115256529
GRCh38: 1:114713907-114713908
9 GNAQ NM_002072.5(GNAQ):c.626A>C (p.Gln209Pro) SNV Pathogenic 375957 rs121913492 GRCh37: 9:80409488-80409488
GRCh38: 9:77794572-77794572
10 GNA11 NM_002067.5(GNA11):c.626A>T (p.Gln209Leu) SNV Pathogenic 376002 rs1057519742 GRCh37: 19:3118942-3118942
GRCh38: 19:3118944-3118944
11 GNA11 NM_002067.5(GNA11):c.626A>C (p.Gln209Pro) SNV Pathogenic 376001 rs1057519742 GRCh37: 19:3118942-3118942
GRCh38: 19:3118944-3118944
12 GNAQ NM_002072.5(GNAQ):c.626A>T (p.Gln209Leu) SNV Pathogenic 375955 rs121913492 GRCh37: 9:80409488-80409488
GRCh38: 9:77794572-77794572
13 MAP2K1 NM_002755.3(MAP2K1):c.157T>C (p.Phe53Leu) SNV Pathogenic 375977 rs1057519728 GRCh37: 15:66727441-66727441
GRCh38: 15:66435103-66435103
14 MAP2K1 NM_002755.3(MAP2K1):c.332T>G (p.Ile111Ser) SNV Pathogenic 375979 rs1057519730 GRCh37: 15:66729124-66729124
GRCh38: 15:66436786-66436786
15 NRAS NM_002524.5(NRAS):c.182_183delinsGG (p.Gln61Arg) Indel Pathogenic 375873 rs1057519695 GRCh37: 1:115256528-115256529
GRCh38: 1:114713907-114713908
16 MAP2K1 NM_002755.3(MAP2K1):c.790C>T (p.Pro264Ser) SNV Pathogenic 375983 rs1057519734 GRCh37: 15:66777424-66777424
GRCh38: 15:66485086-66485086
17 NRAS NM_002524.5(NRAS):c.181C>G (p.Gln61Glu) SNV Pathogenic 375875 rs121913254 GRCh37: 1:115256530-115256530
GRCh38: 1:114713909-114713909
18 NRAS NM_002524.5(NRAS):c.38G>C (p.Gly13Ala) SNV Pathogenic 375877 rs121434596 GRCh37: 1:115258744-115258744
GRCh38: 1:114716123-114716123
19 KIT NM_000222.2(KIT):c.1650A>T (p.Lys550Asn) SNV Pathogenic 375906 rs1057519703 GRCh37: 4:55593584-55593584
GRCh38: 4:54727418-54727418
20 KIT NM_000222.2(KIT):c.2458G>C (p.Asp820His) SNV Pathogenic 375927 rs1057519710 GRCh37: 4:55599332-55599332
GRCh38: 4:54733166-54733166
21 KIT NM_000222.2(KIT):c.1510T>C (p.Phe504Leu) SNV Pathogenic 375904 rs1057519702 GRCh37: 4:55592186-55592186
GRCh38: 4:54726020-54726020
22 KIT NM_000222.2(KIT):c.1679T>C (p.Val560Ala) SNV Pathogenic 375915 rs121913521 GRCh37: 4:55593613-55593613
GRCh38: 4:54727447-54727447
23 KIT NM_000222.2(KIT):c.1650A>C (p.Lys550Asn) SNV Pathogenic 375905 rs1057519703 GRCh37: 4:55593584-55593584
GRCh38: 4:54727418-54727418
24 KIT NM_000222.2(KIT):c.1706T>G (p.Val569Gly) SNV Pathogenic 375918 rs1057519706 GRCh37: 4:55593640-55593640
GRCh38: 4:54727474-54727474
25 KIT NM_000222.2(KIT):c.1674G>C (p.Lys558Asn) SNV Pathogenic 375910 rs200375589 GRCh37: 4:55593608-55593608
GRCh38: 4:54727442-54727442
26 GNAQ NM_002072.5(GNAQ):c.626A>G (p.Gln209Arg) SNV Pathogenic 375956 rs121913492 GRCh37: 9:80409488-80409488
GRCh38: 9:77794572-77794572
27 PTEN NM_000314.8(PTEN):c.633C>A SNV Pathogenic 7836 rs121909232 GRCh37: 10:89712015-89712015
GRCh38: 10:87952258-87952258
28 PTEN NM_001304718.2(PTEN):c.-651G>A SNV Pathogenic 7837 rs121909233 GRCh37: 10:89624281-89624281
GRCh38: 10:87864524-87864524
29 PTEN NM_000314.7(PTEN):c.649G>A (p.Val217Ile) SNV Pathogenic 7838 rs121909234 GRCh37: 10:89717624-89717624
GRCh38: 10:87957867-87957867
30 CDKN2A NM_000077.4(CDKN2A):c.301G>T (p.Gly101Trp) SNV Pathogenic 9412 rs104894094 GRCh37: 9:21971057-21971057
GRCh38: 9:21971058-21971058
31 KIT NM_000222.2(KIT):c.1965T>A (p.Asn655Lys) SNV Pathogenic 375923 rs1057519708 GRCh37: 4:55594262-55594262
GRCh38: 4:54728096-54728096
32 NRAS NM_002524.5(NRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic 39648 rs121913237 GRCh37: 1:115258747-115258747
GRCh38: 1:114716126-114716126
33 NRAS NM_002524.5(NRAS):c.35G>T (p.Gly12Val) SNV Pathogenic 40470 rs121913237 GRCh37: 1:115258747-115258747
GRCh38: 1:114716126-114716126
34 KIT NM_000222.2(KIT):c.1696A>G (p.Asn566Asp) SNV Pathogenic 375917 rs1057519705 GRCh37: 4:55593630-55593630
GRCh38: 4:54727464-54727464
35 KIT NM_000222.2(KIT):c.1657T>A (p.Tyr553Asn) SNV Pathogenic 375907 rs1057519704 GRCh37: 4:55593591-55593591
GRCh38: 4:54727425-54727425
36 KIT NM_000222.2(KIT):c.2458G>T (p.Asp820Tyr) SNV Pathogenic 375928 rs1057519710 GRCh37: 4:55599332-55599332
GRCh38: 4:54733166-54733166
37 KIT NM_000222.2(KIT):c.1676T>A (p.Val559Asp) SNV Pathogenic 13856 rs121913517 GRCh37: 4:55593610-55593610
GRCh38: 4:54727444-54727444
38 CTNNB1 NM_001904.4(CTNNB1):c.110C>A (p.Ser37Tyr) SNV Pathogenic 375894 rs121913403 GRCh37: 3:41266113-41266113
GRCh38: 3:41224622-41224622
39 KIT NM_000222.2(KIT):c.1676T>G (p.Val559Gly) SNV Pathogenic 375912 rs121913517 GRCh37: 4:55593610-55593610
GRCh38: 4:54727444-54727444
40 KIT NM_000222.2(KIT):c.1669T>A (p.Trp557Arg) SNV Pathogenic 375908 rs121913235 GRCh37: 4:55593603-55593603
GRCh38: 4:54727437-54727437
41 KIT NM_000222.2(KIT):c.1679T>A (p.Val560Asp) SNV Pathogenic 375914 rs121913521 GRCh37: 4:55593613-55593613
GRCh38: 4:54727447-54727447
42 KIT NM_000222.2(KIT):c.2485G>C (p.Ala829Pro) SNV Pathogenic 375933 rs1057519713 GRCh37: 4:55602664-55602664
GRCh38: 4:54736498-54736498
43 KIT NM_000222.2(KIT):c.1679T>G (p.Val560Gly) SNV Pathogenic 375916 rs121913521 GRCh37: 4:55593613-55593613
GRCh38: 4:54727447-54727447
44 BRAF NM_004333.6(BRAF):c.1798_1799delinsAA (p.Val600Lys) Indel Pathogenic 375941 rs121913227 GRCh37: 7:140453136-140453137
GRCh38: 7:140753336-140753337
45 NRAS NM_002524.5(NRAS):c.38G>T (p.Gly13Val) SNV Pathogenic 375876 rs121434596 GRCh37: 1:115258744-115258744
GRCh38: 1:114716123-114716123
46 NRAS NM_002524.5(NRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic 13899 rs121434595 GRCh37: 1:115258745-115258745
GRCh38: 1:114716124-114716124
47 KIT NM_000222.2(KIT):c.1727T>C (p.Leu576Pro) SNV Pathogenic 375919 rs121913513 GRCh37: 4:55593661-55593661
GRCh38: 4:54727495-54727495
48 BRAF NM_001374258.1(BRAF):c.1909C>G (p.Leu637Val) SNV Pathogenic 13969 rs121913369 GRCh37: 7:140453146-140453146
GRCh38: 7:140753346-140753346
49 KIT NM_000222.2(KIT):c.1965T>G (p.Asn655Lys) SNV Pathogenic 375924 rs1057519708 GRCh37: 4:55594262-55594262
GRCh38: 4:54728096-54728096
50 BRAF NM_004333.6(BRAF):c.1782T>G (p.Asp594Glu) SNV Pathogenic 375944 rs121913337 GRCh37: 7:140453153-140453153
GRCh38: 7:140753353-140753353

Cosmic variations for Skin Carcinoma:

9 (show top 50) (show all 2121)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM152022165 YES1 skin,eye,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 48
2 COSM136837388 YES1 skin,eye,carcinoma,squamous cell carcinoma c.866G>A p.G289E 18:743289-743289 48
3 COSM89895645 YES1 skin,eye,carcinoma,squamous cell carcinoma c.851G>A p.G284E 18:743289-743289 48
4 COSM150677496 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2050C>T p.R684C 9:132903794-132903794 48
5 COSM85720102 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
6 COSM149039828 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2062C>T p.R688C 9:132903794-132903794 48
7 COSM150537076 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.1912C>T p.R638C 9:132903794-132903794 48
8 COSM151334154 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
9 COSM111041127 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
10 COSM147983627 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2062C>T p.R688C 9:132903794-132903794 48
11 COSM148035069 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2047C>T p.R683C 9:132903794-132903794 48
12 COSM151875202 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.2065C>T p.R689C 9:132903794-132903794 48
13 COSM133087519 TSC1 skin,eye,carcinoma,squamous cell carcinoma c.1912C>T p.R638C 9:132903794-132903794 48
14 COSM90145852 TRAF7 skin,eye,carcinoma,squamous cell carcinoma c.349G>A p.E117K 16:2171264-2171264 48
15 COSM106059757 TP53 skin,hand,carcinoma,squamous cell carcinoma c.260C>A p.P87Q 17:7676109-7676109 48
16 COSM143944147 TP53 skin,arm,carcinoma,squamous cell carcinoma c.265C>T p.R89W 17:7674221-7674221 48
17 COSM112354551 TP53 skin,hand,carcinoma,squamous cell carcinoma c.565G>A p.A189T 17:7674966-7674966 48
18 COSM112254631 TP53 skin,face,carcinoma,squamous cell carcinoma c.586C>T p.R196* 17:7674945-7674945 48
19 COSM111759858 TP53 skin,hand,carcinoma,squamous cell carcinoma c.856G>A p.E286K 17:7673764-7673764 48
20 COSM143943797 TP53 skin,neck,carcinoma,squamous cell carcinoma c.266G>A p.R89Q 17:7674220-7674220 48
21 COSM121875437 TP53 skin,face,carcinoma,squamous cell carcinoma c.178C>T p.Q60* 17:7674957-7674957 48
22 COSM143388508 TP53 skin,face,carcinoma,squamous cell carcinoma c.629G>C p.R210T 17:7674217-7674217 48
23 COSM111758868 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 48
24 COSM142560384 TP53 skin,face,carcinoma,squamous cell carcinoma c.616G>T p.G206C 17:7674230-7674230 48
25 COSM145161899 TP53 skin,hand,carcinoma,squamous cell carcinoma c.833A>G p.Q278R 17:7673578-7673578 48
26 COSM144021997 TP53 skin,face,carcinoma,squamous cell carcinoma c.421C>T p.P141S 17:7675158-7675158 48
27 COSM144020497 TP53 skin,eye,carcinoma,squamous cell carcinoma c.806G>C p.R269T 17:7673781-7673781 48
28 COSM144658487 TP53 skin,face,carcinoma,squamous cell carcinoma c.143C>A p.P48Q 17:7676109-7676109 48
29 COSM142639459 TP53 skin,face,carcinoma,squamous cell carcinoma c.597T>A p.C199* 17:7674249-7674249 48
30 COSM105620390 TP53 skin,face,carcinoma,squamous cell carcinoma c.733G>T p.G245C 17:7674230-7674230 48
31 COSM112254266 TP53 skin,hand,carcinoma,squamous cell carcinoma c.673-1G>A p.? 17:7674291-7674291 48
32 COSM112283184 TP53 skin,arm,carcinoma,squamous cell carcinoma c.859G>A p.E287K 17:7673761-7673761 48
33 COSM112263720 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 48
34 COSM144313019 TP53 skin,eye,carcinoma,squamous cell carcinoma c.470G>T p.R157L 17:7674944-7674944 48
35 COSM93239210 TP53 skin,face,carcinoma,squamous cell carcinoma c.706T>C p.Y236H 17:7674257-7674257 48
36 COSM145019215 TP53 skin,hand,carcinoma,squamous cell carcinoma c.739G>A p.E247K 17:7673764-7673764 48
37 COSM105620642 TP53 skin,face,carcinoma,squamous cell carcinoma c.742C>T p.R248W 17:7674221-7674221 48
38 COSM143949062 TP53 skin,face,carcinoma,squamous cell carcinoma c.263A>C p.N88T 17:7674223-7674223 48
39 COSM111775215 TP53 skin,face,carcinoma,squamous cell carcinoma c.746G>C p.R249T 17:7674217-7674217 48
40 COSM122740947 TP53 skin,eye,carcinoma,squamous cell carcinoma c.443G>C p.R148T 17:7673781-7673781 48
41 COSM144129318 TP53 skin,face,carcinoma,squamous cell carcinoma c.229T>C p.Y77H 17:7674257-7674257 48
42 COSM144088618 TP53 skin,face,carcinoma,squamous cell carcinoma c.160C>T p.R54* 17:7674894-7674894 48
43 COSM87910628 TP53 skin,face,carcinoma,squamous cell carcinoma c.772G>A p.E258K 17:7674191-7674191 48
44 COSM144662686 TP53 skin,face,carcinoma,squamous cell carcinoma c.715C>T p.P239S 17:7673788-7673788 48
45 COSM144650676 TP53 skin,face,carcinoma,squamous cell carcinoma c.457C>T p.Q153* 17:7674957-7674957 48
46 COSM142560553 TP53 skin,face,carcinoma,squamous cell carcinoma c.625C>T p.R209W 17:7674221-7674221 48
47 COSM144309924 TP53 skin,hand,carcinoma,squamous cell carcinoma c.701G>A p.R234H 17:7673802-7673802 48
48 COSM93194159 TP53 skin,face,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 48
49 COSM142560281 TP53 skin,neck,carcinoma,squamous cell carcinoma c.626G>A p.R209Q 17:7674220-7674220 48
50 COSM122737048 TP53 skin,eye,carcinoma,squamous cell carcinoma c.191G>T p.R64L 17:7674944-7674944 48

Expression for Skin Carcinoma

Search GEO for disease gene expression data for Skin Carcinoma.

Pathways for Skin Carcinoma

Pathways related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 236)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.39 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
2
Show member pathways
14.21 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
3
Show member pathways
14.06 TP53 RAF1 PTEN PDGFRA NRAS MAP2K1
4
Show member pathways
14.05 TP53 RAF1 PTEN PDGFRA NRAS MAP2K1
5
Show member pathways
14 SNAPC5 RAF1 PIK3CA NRAS MAP2K1 HRAS
6
Show member pathways
13.94 TP53 RAF1 PDGFRA NRAS MAP2K1 KIT
7
Show member pathways
13.9 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
8
Show member pathways
13.87 TP53 RAF1 PDGFRA NRAS MAP2K1 KIT
9
Show member pathways
13.78 TP53 RAF1 PIK3CA PDGFRA NRAS MAP2K1
10
Show member pathways
13.77 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
11
Show member pathways
13.74 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
12
Show member pathways
13.68 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
13
Show member pathways
13.66 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
14
Show member pathways
13.66 RAF1 PTEN PIK3CA NRAS MAP2K1 HRAS
15
Show member pathways
13.62 TP53 RAF1 PTEN PDGFRA NRAS KIT
16
Show member pathways
13.6 TP53 RAF1 PIK3CA PDGFRA NRAS MAP2K1
17
Show member pathways
13.55 RAF1 PTEN PDGFRA NRAS MAP2K1 KIT
18
Show member pathways
13.51 TP53 RAF1 PIK3CA NRAS HRAS GNAQ
19
Show member pathways
13.51 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
20
Show member pathways
13.46 PTEN PDGFRA NRAS KIT HRAS CTNNB1
21
Show member pathways
13.46 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
22
Show member pathways
13.35 TP53 RAF1 PTEN PIK3CA NRAS MAP2K1
23
Show member pathways
13.32 TP53 RAF1 PTEN PDGFRA NRAS MAP2K1
24
Show member pathways
13.29 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
25
Show member pathways
13.26 TP53 PTEN PIK3CA PDGFRA KIT AKT1
26
Show member pathways
13.26 RAF1 PIK3CA NRAS MAP2K1 HRAS GNAQ
27
Show member pathways
13.26 TP53 RAF1 NRAS MAP2K1 HRAS GNA11
28
Show member pathways
13.21 TP53 RAF1 PTEN PIK3CA PDGFRA NRAS
29
Show member pathways
13.2 RAF1 PTEN NRAS MAP2K1 HRAS CTNNB1
30
Show member pathways
13.18 RAF1 PTEN PIK3CA PDGFRA NRAS MAP2K1
31
Show member pathways
13.16 RAF1 PIK3CA NRAS MAP2K1 HRAS GNAQ
32
Show member pathways
13.15 RAF1 PTEN PIK3CA PDGFRA NRAS MAP2K1
33
Show member pathways
13.12 RAF1 PTEN PIK3CA NRAS MAP2K1 HRAS
34
Show member pathways
13.1 TP53 RAF1 PTEN NRAS MAP2K1 HRAS
35
Show member pathways
13.08 RAF1 NRAS MAP2K1 HRAS GNA11 CTNNB1
36
Show member pathways
13.08 RAF1 PTEN NRAS MAP2K1 HRAS GNAQ
37 13.06 TP53 RAF1 PDGFRA NRAS MAP2K1 KIT
38
Show member pathways
13.06 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
39
Show member pathways
13.03 RAF1 PTEN PIK3CA MAP2K1 HRAS BRAF
40
Show member pathways
13.02 TP53 RAF1 PIK3CA MAP2K1 CDK4 AKT1
41
Show member pathways
13.01 TP53 PTEN PIK3CA PDGFRA NRAS KIT
42
Show member pathways
12.99 TP53 RAF1 PIK3CA NRAS MAP2K1 HRAS
43
Show member pathways
12.99 TP53 RAF1 PTEN PIK3CA NRAS MAP2K1
44
Show member pathways
12.98 TP53 RAF1 PIK3CA PDGFRA NRAS MAP2K1
45
Show member pathways
12.96 RAF1 PIK3CA MAP2K1 HRAS CTNNB1 AKT1
46
Show member pathways
12.96 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
47
Show member pathways
12.95 TP53 RAF1 PDGFRA NRAS MAP2K1 HRAS
48
Show member pathways
12.94 RAF1 MAP2K1 HRAS GNA11 BRAF AKT1
49
Show member pathways
12.94 RAF1 PIK3CA NRAS MITF MAP2K1 HRAS
50
Show member pathways
12.94 RAF1 NRAS MAP2K1 HRAS GNA11 CDKN2A

GO Terms for Skin Carcinoma

Cellular components related to Skin Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10 RAF1 PTEN PIK3CA PDGFRA NRAS MC1R
2 cytoplasm GO:0005737 9.55 TP53 RAF1 PTEN PIK3CA PDGFRA MITF
3 protein-containing complex GO:0032991 9.5 TP53 PDGFRA MITF CTNNB1 CDKN2A CDK4

Biological processes related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.2 TP53 RAF1 MITF MC1R HRAS CTNNB1
2 positive regulation of transcription, DNA-templated GO:0045893 10.15 TP53 MITF MAP2K1 CTNNB1 CDKN2A AKT1
3 apoptotic process GO:0006915 10.14 TP53 RAF1 PTEN HRAS CDKN2A AKT1
4 signal transduction GO:0007165 10.1 RAF1 NRAS MC1R MAP2K1 KIT HRAS
5 intracellular signal transduction GO:0035556 10.09 RAF1 MC1R KIT BRAF AKT1
6 positive regulation of cell proliferation GO:0008284 10.05 PTEN PDGFRA KIT HRAS CTNNB1 CDK4
7 negative regulation of apoptotic process GO:0043066 10.04 TP53 RAF1 PTEN MITF CTNNB1 BRAF
8 negative regulation of gene expression GO:0010629 10.03 TP53 MAP2K1 HRAS CTNNB1 AKT1
9 positive regulation of apoptotic process GO:0043065 10.01 TP53 PTEN CTNNB1 CDKN2A CDK4 AKT1
10 negative regulation of cell proliferation GO:0008285 10 TP53 RAF1 PTEN MAP2K1 HRAS CTNNB1
11 protein stabilization GO:0050821 9.99 TP53 PTEN GNAQ CDKN2A
12 positive regulation of protein kinase B signaling GO:0051897 9.97 PIK3CA PDGFRA MC1R KIT
13 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.97 PTEN PDGFRA MAP2K1 HRAS BRAF
14 protein phosphorylation GO:0006468 9.97 RAF1 PIK3CA PDGFRA MAP2K1 KIT CDK4
15 peptidyl-tyrosine phosphorylation GO:0018108 9.94 PDGFRA MAP2K1 KIT BRAF
16 cell cycle arrest GO:0007050 9.93 TP53 MAP2K1 HRAS CDKN2A
17 positive regulation of DNA-binding transcription factor activity GO:0051091 9.92 PTEN KIT CTNNB1 AKT1
18 platelet activation GO:0030168 9.91 RAF1 PIK3CA GNAQ GNA11
19 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.88 RAF1 PIK3CA BRAF AKT1
20 regulation of cell proliferation GO:0042127 9.88 TP53 MITF KIT CTNNB1 CDK4 BRAF
21 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.87 PTEN CDKN2A CDK4
22 somatic stem cell population maintenance GO:0035019 9.87 RAF1 KIT BRAF
23 hematopoietic progenitor cell differentiation GO:0002244 9.86 TP53 PDGFRA KIT
24 Ras protein signal transduction GO:0007265 9.85 TP53 NRAS HRAS CDKN2A
25 epidermal growth factor receptor signaling pathway GO:0007173 9.83 PIK3CA BRAF AKT1
26 cellular response to nerve growth factor stimulus GO:1990090 9.83 PTEN BRAF AKT1
27 protein kinase B signaling GO:0043491 9.82 PTEN PIK3CA AKT1
28 phosphatidylinositol 3-kinase signaling GO:0014065 9.82 PTEN PIK3CA AKT1
29 phosphorylation GO:0016310 9.81 RAF1 PIK3CA PDGFRA MAP2K1 KIT CDKN2A
30 pigmentation GO:0043473 9.8 MITF MC1R KIT
31 MAPK cascade GO:0000165 9.8 RAF1 PDGFRA NRAS MAP2K1 KIT HRAS
32 thymus development GO:0048538 9.78 RAF1 MAP2K1 CTNNB1 BRAF
33 cellular senescence GO:0090398 9.77 MAP2K1 HRAS CDKN2A
34 thyroid gland development GO:0030878 9.76 RAF1 MAP2K1 BRAF
35 face development GO:0060324 9.73 RAF1 MAP2K1 BRAF
36 developmental pigmentation GO:0048066 9.71 KIT GNA11
37 anoikis GO:0043276 9.71 PIK3CA AKT1
38 negative regulation of cell size GO:0045792 9.71 PTEN AKT1
39 cellular response to insulin-like growth factor stimulus GO:1990314 9.7 PTEN FBN1
40 somatic stem cell division GO:0048103 9.7 KIT CDKN2A
41 phototransduction, visible light GO:0007603 9.7 GNAQ GNA11
42 positive regulation of phospholipase C activity GO:0010863 9.7 PDGFRA KIT HRAS
43 positive regulation of DNA-templated transcription, initiation GO:2000144 9.68 MITF CTNNB1
44 entrainment of circadian clock GO:0009649 9.68 GNAQ GNA11
45 trachea formation GO:0060440 9.67 MAP2K1 CTNNB1
46 myeloid progenitor cell differentiation GO:0002318 9.67 KIT BRAF
47 cellular response to decreased oxygen levels GO:0036294 9.65 PTEN AKT1
48 canonical Wnt signaling pathway involved in negative regulation of apoptotic process GO:0044336 9.61 MITF CTNNB1
49 regulation of axon regeneration GO:0048679 9.61 PTEN MAP2K1 BRAF
50 heart development GO:0007507 9.5 TP53 RAF1 PTEN MAP2K1 GNA11 FBN1

Molecular functions related to Skin Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.4 TP53 SNAPC5 RAF1 PTEN PIK3CA PDGFRA
2 ATP binding GO:0005524 10.02 TP53 RAF1 PIK3CA PDGFRA MAP2K1 KIT
3 protein kinase binding GO:0019901 9.92 TP53 PTEN CTNNB1 CDKN2A AKT1
4 enzyme binding GO:0019899 9.89 TP53 RAF1 PTEN CTNNB1 AKT1
5 protein serine/threonine kinase activity GO:0004674 9.8 RAF1 PIK3CA MAP2K1 CDK4 BRAF AKT1
6 protein kinase activity GO:0004672 9.8 RAF1 PDGFRA MAP2K1 KIT CDK4 BRAF
7 protein tyrosine kinase activity GO:0004713 9.73 PDGFRA MAP2K1 KIT BRAF
8 nucleotide binding GO:0000166 9.73 RAF1 PIK3CA PDGFRA NRAS MAP2K1 KIT
9 protein-containing complex binding GO:0044877 9.7 RAF1 PDGFRA NRAS HRAS FBN1 CDK4
10 disordered domain specific binding GO:0097718 9.63 TP53 CTNNB1 CDKN2A
11 MDM2/MDM4 family protein binding GO:0097371 9.51 TP53 CDKN2A
12 type 2A serotonin receptor binding GO:0031826 9.48 GNAQ GNA11
13 kinase activity GO:0016301 9.28 RAF1 PIK3CA PDGFRA MAP2K1 KIT CDKN2A

Sources for Skin Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....